Literature DB >> 11339619

Aggressive atropinisation and continuous pralidoxime (2-PAM) infusion in patients with severe organophosphate poisoning: experience of a northwest Indian hospital.

S Singh1, D Chaudhry, D Behera, D Gupta, S K Jindal.   

Abstract

OBJECTIVE: The aim of the study was to find whether continuous pralidoxime (2-PAM) infusion along with aggressive atropinisation improves the outcome in patients with severe organophosphate poisoning who require assisted ventilation.
METHODS: Sixteen patients admitted to the respiratory intensive care unit (RICU) with severe organophosphate poisoning and requiring assisted ventilation were included in the study. The compounds involved were phorate (six), dichlorvos (four), oxydimeton methyl (one), monocrotophos (one), methyl parathion (one) and in three it was unknown. After decontamination, they were given intravenous (iv) bolus atropine 5 mg at onset and then 2.5 mg every 5-10 min till atropinisation was achieved, and then maintained either by intermittent bolus doses or by continuous infusion if the required dose was large. They were also given continuous iv infusion of 2-PAM in dose of 7.5 mg/ kg body weight/h (maximum 500 mg/h) after an initial bolus dose of 2 g.
RESULTS: The mean (+/-S.D.) dose of atropine was 735.02 +/- 742.98 mg (range 85-3000 mg) with maximum dose on day 1. The mean (+/-S.D) duration of 2-PAM infusion was 96.4+/-49.4 h (range 10-216 h). The mean (+/-S.D) duration of mechanical ventilation (MV) was 131.5 +/- 95.65 h (range 4-336 h). Fourteen patients could be successfully extubated and two died of bronchopneumonia and sepsis (mortality 12.5%).
CONCLUSION: Continuous 2-PAM infusion along with aggressive atropinisation after initial decontamination improved the outcome but not the duration of MV in severely intoxicated patients with organophosphate compounds who required assisted ventilation in this case series.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11339619     DOI: 10.1191/096032701671437581

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  8 in total

1.  Organophosphorous Poisoning : an Evidence Based Approach.

Authors:  Surjit Singh
Journal:  Med J Armed Forces India       Date:  2011-07-21

2.  Regeneration of Red Cell Cholinesterase Activity Following Pralidoxime (2-PAM) Infusion in First 24 h in Organophosphate Poisoned Patients.

Authors:  Parul Goel; Nidhi Gupta; Surjit Singh; Ashish Bhalla; Navneet Sharma; K D Gill
Journal:  Indian J Clin Biochem       Date:  2011-08-02

3.  Factors associated with outcomes in organophosphate and carbamate poisoning: a retrospective study.

Authors:  B Shrikar Reddy; Teny Grace Skaria; Sravani Polepalli; Sudha Vidyasagar; Mahadev Rao; Vijayanarayana Kunhikatta; Sreedharan Nair; Girish Thunga
Journal:  Toxicol Res       Date:  2020-02-07

Review 4.  Oximes in acute organophosphorus pesticide poisoning: a systematic review of clinical trials.

Authors:  M Eddleston; L Szinicz; P Eyer; N Buckley
Journal:  QJM       Date:  2002-05

5.  Evaluation of the joint toxicity of chlorpyrifos ethyl and fenobucarb on climbing perch (Anabas testudineus) from rice fields in the Mekong Delta, Vietnam.

Authors:  Nguyen Thanh Tam; Håkan Berg; Nguyen Van Cong
Journal:  Environ Sci Pollut Res Int       Date:  2016-06-02       Impact factor: 4.223

Review 6.  Treatment of neuroterrorism.

Authors:  Katharina M Busl; Thomas P Bleck
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

7.  Predictors of Morbidity and Mortality in Organophosphorus Poisoning: A Case Study in Rural Hospital in Karnataka, India.

Authors:  Tanveer Hassan Banday; Bharath Tathineni; Mehul Surendra Desai; Vikas Naik
Journal:  N Am J Med Sci       Date:  2015-06

Review 8.  Suicide by pesticide poisoning in India: a review of pesticide regulations and their impact on suicide trends.

Authors:  Toby Bonvoisin; Leah Utyasheva; Duleeka Knipe; David Gunnell; Michael Eddleston
Journal:  BMC Public Health       Date:  2020-02-19       Impact factor: 3.295

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.